CHANGES IN THE PARAMETERS OF 24-HOUR BLOOD PRESSURE MONITORING AND ARTERIAL STIFFNESS IN PATIENTS WITH HYPERTENSION AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATED WITH VALSARTAN

Aim. To study changes in the parameters of the 24-hour blood pressure (BP) monitoring and arterial stiffness (AS) in patients with arterial hypertension (HT) and chronic obstructive pulmonary disease (COPD) treated with angiotensin II receptors blocker, valsartan.

Material and methods. Men with HT and COPD (n=23), who have been receiving valsartan with starting dose 80 mg/day for 6 months as antihypertensive therapy were included into the study. If target BP was not achieved, correction of the valsartan dose was carried out with the hydrochlorothiazide addition when needed. Clinical examination, 24-hour BP and AS monitoring using BPLab MnSDP-2 monitor ("Petr TELEGIN",Russia), clinical evaluation of COPD were performed.

Results. Abnormal circadian BP profile and the elastic properties of arteries were diagnosed in the majority of hypertensive patients with COPD. Valsartan therapy allowed to achieve target BP levels in 100% of patients, normalization of circadian BP profile in 56.5%, improvement in AS parameters: a significant increase in PTT2 (from 89.6±14.3 to 94.4±18.4 ms), reduction of (dP/dt)max (from 566.6±117.9 to 518.8±146.2 mmHg/s), AIx (from -4.0±15.2 to -11.6±20.8 %) as compared to the baseline. Circadian changes in daily parameters of AS in studied patients with the most obvious night-time abnormalities of the elastic properties of arteries were detected. Valsartan intake led to Alx reduction at night-time.

Conclusion. Valsartan-based therapy in hypertensive patients with concomitant COPD demonstrated a high antihypertensive efficacy and favorable changes in the elastic properties of the vascular wall that confirm its organoprotective effect.

1. Global Strategy for Diagnosis, Management, and Prevention of COPD (revised 2011). Vancouver (WA): Global Initiative for Chronic Obstructive Lung Disease, Inc; 2011.

2. Karoly NA, Rebrov AP. Comorbidity in patients with chronic obstructive pulmonary disease: the place of cardiovascular disease. Rational Pharmacother Card 2009; (4): 9-16. Russian (Кароли Н.А., Ребров А.П. Коморбидность у больных хронической обструктивной болезнью легких: место кардиоваскулярной патологии. Рациональная Фармакотерапия в Кардиологии 2009; (4): 9-16).

3. Diagnosis and treatment of patients with arterial hypertension and chronic obstructive pulmonary disease (Recommendation Russian Medical Society of Hypertension and Russian Respiratory Society). Systemic Hypertension 2013; (1): 5-34. Russian (Диагностика и лечение пациентов с артериальной гипертонией и хронической обструктивной болезнью легких (Рекомендации Российского медицинского общества по артериальной гипертонии и Российского респираторного общества). Системные Гипертензии 2013; (1): 5-34).

4. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Hypertension 2013,31:1281-1357.

5. National guidelines for diagnosis and treatment of hypertension (4th revision). Systemic Hypertension 2010; (3): 5-26. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертензии (4-й пересмотр). Системные Гипертензии 2010; (3): 5-26).

6. Makarova MA, Avdeev SN. Arterial stiffness and endothelial dysfunction in patients with chronic obstructive pulmonary disease. Pulmonology 2011; (4): 109-17. Russian (Макарова М.А., Авдеев С.Н. Артериальная ригидность и эндотелиальная дисфункция у больных хронической обструктивной болезнью легких. Пульмонология 2011; (4): 109-17).

7. Karoly NA, Rebrov AP. Arterial stiffness in patients with chronic obstructive pulmonary disease. Therapeutic Archive 2012; (3): 12-6. Russian (Кароли Н.А., Ребров А.П. Жесткость артерий у больных хронической обструктивной болезнью легких. Терапевтический Архив 2012; (3): 12-6).

8. Geltser BI, Brody TA, Nevzorova VA. Evaluation of arterial stiffness in patients with chronic obstructive pulmonary disease. Pulmonology 2008; (1): 45-50. Russian (Гельцер Б.И., Бродская Т.А., Невзорова В.А. Оценка артериальной ригидности у больных хронической обструктивной болезнью легких. Пульмонология 2008; (1): 45-50).

9. Rebrov AP, Nikitina NM, Karoly NA, et al. Arterial stiffness, depending on the presence of risk factors for cardiovascular diseases. Therapeutic Archive 2009; (3): 54-7. Russian (Ребров А.П., Никитина Н.М., Кароли Н.А., и др. Жесткость артерий в зависимости от наличия факторов риска развития сердечно-сосудистых заболеваний. Терапевтический Архив 2009; (3): 54-7).

10. Abirova ES, Gorbunov VM, Egorkina NV, et al. Daily monitoring and other indicators of arterial stiffness in evaluating the effectiveness of antihypertensive therapy. Arterial Hypertension 2010, 16 (6): 621 8. Russian (Абирова Э.С., Горбунов В.М., Егоркина Н.В. и др. Суточное мониторирование показателей артериальной ригидности при оценке эффективности антигипертензивной терапии. Артериальная Гипертензия 2010; 16 (6): 621-8).

11. Moiseeva NM, Ponomarev YA, Sergeeva MV, Rogoza AN. Estimation of the rigidity of the great arteries according bifunctional BP monitoring and ECG device BPLab ®. Arterial Hypertension 2007,

12. (1): 1-5. Russian (Моисеева Н.М., Пономарев Ю.А., Сергеева М.В., Рогоза А.Н. Оценка показателей ригидности магистральных артерий по данным бифункционального суточного мониторирования АД и ЭКГ прибором BPLab®. Артериальная гипертензия 2007; 13 (1): 1-5).

13. User Guide BPLab v.3.0 (04.2009 edition) Part 1. Nizhny Novgorod: OOO Petr Telegin; 2009. Russian (Руководство пользователя ПО BPLab v.3.0 (редакция 04.2009) Часть 1. Нижний Новгород: ООО Петр Телегин; 2009).

14. Xie Q.Y., Wang Y.J., Sun Z.L., Yang T.L. Effects of valsartan and indapamide on plasma cytokines in essential hypertension. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2006; 31 (5): 629-34.

15. Manabe S., Okura T., Watanabe S. et al. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmacol 2005; 46(6): 735-9.

16. Klingbeil A.U., John S., Schneider M.P. et al. Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens 2003; 16 (2): 123-8.

17. Karalliedde J., Smith A., DeAngelis L. et al. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension 2008; 51: 1617-23.

18. Nakamura T., Fujii S., Hoshino J. et al. Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients. Hypertens Res 2005; 28(12): 937-43.

19. Sturov NV. Organoprotective effects of angiotensin II receptor blockers (sartans). Outpatient Physician Handbook 2009; (8): 31-4. Russian (Стуров Н.В. Органопротективные свойства блокаторов рецепторов ангиотензина II (сартанов). Справочник Поликлинического Врача 2009; (8): 31-4).